Cadus Management Performance

Cadus Corporation -- USA Stock  

USD 1.26  0.01  0.8%

Analysis of Cadus manpower and management performance can provide insight into Cadus stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with Cadus future performance. Please see also Stocks Correlation.

Cadus Management Effectiveness

The company has return on total asset (ROA) of (1.14) % which means that it has lost $1.14 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (1.8) % meaning that it created substantial loss on money invested by shareholders.

Cadus Stakeholders

Hunter Gary CEO and President and Director
David Blitz CFO, Principal Accounting Officer, Treasurer and Secretary
Jack Wasserman Independent Director
Peter Liebert Independent Director, Ph.D
James Broach Director of Research and Director, Ph.D

Leadership

Cadus Top Executives
Hunter Gary  CEO
CEO and President and Director

Tenure Analysis

Cadus Employment Tenure
Cadus employes about 5 people. The company is managed by 5 executives with total tenure of roughly 35 years, averanging almost 7.0 years of service per executive having 1.0 employee per reported executive.

Manpower Efficiency

Return on Cadus Manpower
Net Loss Per Employee 147.3 K
Net Loss Per Executive 147.3 K
Working Capital Per Employee 8.2 M
Working Capital Per Executive 8.2 M

Number of Employees

Cadus Number of Employees Analysis
Cadus Corporation is rated below average in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 316. Cadus claims roughly 5.0 in number of employees contributing just under 2% to stocks in Biotechnology industry.

Earnings Per Share

Cadus Earnings Per Share
According to company disclosure Cadus Corporation has Earnings Per Share of -0.03 times. This is 104.0% lower than that of the Healthcare sector, and 200.0% lower than that of Biotechnology industry, The Earnings Per Share for all stocks is 101.3% higher than the company.
Earnings per Share is one of the most important measures of the current share price of a firm, and is used by investors to determine the company overall profitability; especially when it is compared to the EPS of similar companies.